Spark Therapeutics enters into definitive merger agreement with Roche

Roche to acquire Spark Therapeutics for $114.50 per share representing a total equity value of $4.8 billion. Spark Therapeutics will continue its operations in Philadelphia as an independent company within the Roche Group Transaction expected to close in Q2, 2019.

Read more at the company website.